Pure Global

Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation - Trial 2009-010261-23

Access comprehensive clinical trial information for 2009-010261-23 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently status unknown. The study focuses on Cystic Fibrosis.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2009-010261-23
Trial Details
EU Clinical Trials Register โ€ข 2009-010261-23
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

Study Focus

Cystic Fibrosis

Sponsor & Location

Vertex Pharmaceuticals Incorporated

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

- History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject

ICD-10 Classifications

Cystic fibrosis
Cystic fibrosis, unspecified
Cystic fibrosis with other manifestations
Cystic fibrosis with pulmonary manifestations
Cystic fibrosis with intestinal manifestations

Data Source

EU Clinical Trials Register

2009-010261-23

Non-Device Trial